- Home
- OMCL vs KROS Comparison
OMCL vs KROS Comparison
Compare OMCL & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- KROS
- Stock Information
- Founded
- OMCL 1992
- KROS 2015
- Country
- OMCL United States
- KROS United States
- Employees
- OMCL N/A
- KROS N/A
- Industry
- OMCL Computer Manufacturing
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- KROS Health Care
- Exchange
- OMCL Nasdaq
- KROS Nasdaq
- Market Cap
- OMCL 2.0B
- KROS 633.5M
- IPO Year
- OMCL 2001
- KROS 2020
- Fundamental
- Price
- OMCL $44.48
- KROS $16.23
- Analyst Decision
- OMCL Buy
- KROS Buy
- Analyst Count
- OMCL 6
- KROS 11
- Target Price
- OMCL $52.00
- KROS $68.83
- AVG Volume (30 Days)
- OMCL 536.0K
- KROS 1.9M
- Earning Date
- OMCL 02-06-2025
- KROS 02-26-2025
- Dividend Yield
- OMCL N/A
- KROS N/A
- EPS Growth
- OMCL N/A
- KROS N/A
- EPS
- OMCL N/A
- KROS N/A
- Revenue
- OMCL $1,064,205,999.00
- KROS $651,000.00
- Revenue This Year
- OMCL N/A
- KROS $224.66
- Revenue Next Year
- OMCL $5.24
- KROS N/A
- P/E Ratio
- OMCL N/A
- KROS N/A
- Revenue Growth
- OMCL N/A
- KROS 8037.50
- 52 Week Low
- OMCL $25.12
- KROS $15.38
- 52 Week High
- OMCL $55.75
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- OMCL 47.66
- KROS 23.95
- Support Level
- OMCL $42.80
- KROS $15.33
- Resistance Level
- OMCL $44.69
- KROS $17.25
- Average True Range (ATR)
- OMCL 1.42
- KROS 1.36
- MACD
- OMCL -0.10
- KROS -0.44
- Stochastic Oscillator
- OMCL 41.00
- KROS 20.19
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.